Claims for Patent: 8,900,566

Summary for Patent: 8,900,566

Title:	Hepatitis C virus inhibitors
Abstract:	The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Inventor(s):	Belema; Makonen (North Haven, CT), Nguyen; Van N. (Middletown, CT)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	14/030,199
Patent Claims:	1. A method of inhibiting and/or relieving an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-met- hylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2- -yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate, or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 further comprising administering one or two additional compounds having anti-HCV activity prior to, after or simultaneously with methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-met- hylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2- -yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate, or a pharmaceutically acceptable salt thereof. 3. The method of claim 2 wherein at least one of the additional compounds having anti-HCV activity is an interferon or ribavirin. 4. The method of claim 3 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau. 5. The method of claim 2 wherein at least one of the additional compounds having anti-HCV activity is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiquimod, ribavirin, an inosine 5'-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine. 6. The method of claim 2 wherein at least one of the additional compounds having anti-HCV activity is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection. 7. The method of claim 2 wherein at least one of the additional compounds having anti-HCV activity is effective to inhibit the function of a target selected from HCV serine protease and HCV polymerase.